ライフサイエンスコーパス: galectin 1

1 -glycans able to establish interactions with Galectin-1.

2 were measured in the presence and absence of galectin-1.

3 (nanoplexes) to inhibit gene expression for galectin-1.

4 ginex, we had yet to prove that 0118 targets galectin-1.

5 e-host cell interaction via binding to human galectin-1.

6 ender thymocytes susceptible or resistant to galectin-1.

7 for a ubiquitous galactoside-binding lectin galectin-1.

8 as mediators of the DC activation effects of galectin-1.

9 e 2 O-glycan expression or susceptibility to galectin-1.

10 om a patient with MF, were also resistant to galectin-1.

11 that allow recognition and cross-linking by galectin-1.

12 equired for maximal T cell susceptibility to galectin-1.

13 te BCR signaling through an association with galectin-1.

14 n receptors distinct from that recognized by galectin-1.

15 n contrast to the CD45 clustering induced by galectin-1.

16 pressing the beta-galactoside-binding lectin galectin-1.

17 toplasmic levels of the nanocluster scaffold galectin-1.

18 dothelial cells against apoptosis induced by Galectin-1.

19 e-arene interactions for galectin-3 than for galectin-1.

20 galectin family of glycan binding proteins (galectins-1, -2, and -4) induce PS exposure in a carbohy

21 ated in solid phase assays using recombinant galectin-1, -3, -8, confirming selectivity for galectin-

22 otrophoblast of the human placenta expresses galectins-1, -3, and -8 in vivo and in vitro.

23 Galectin-1, a beta-galactoside-binding lectin, is involv

24 Galectin-1, a beta-galactoside-binding protein highly ex

25 Galectin-1, a member of the conserved family of carbohyd

26 We examined the effects of galectin-1 ablation in the context of class-I-restricted

27 The latter two are specific features of galectin-1-activated DCs.

28 We previously showed that galectin-1 activates human monocyte-derived dendritic ce

29 at complexes containing H-ras conformers and galectin-1 affect both the number and lifetime of nanocl

30 We propose that galectin-1 aids in discriminating TCR-directed fate deci

31 nfirming previous studies, morphine alone or galectin-1 alone enhance HIV-1 infection of MDMs.

32 many of the same DC maturation genes as LPS, galectin-1 also uniquely up-regulated a significant subs

33 CD45 is a glycoprotein receptor for galectin-1, an endogenous lectin that can trigger lympho

34 We demonstrate that galectin-1 and -3 are expressed by the human cervical an

35 ozoan derivatives to dissect the function of galectin-1 and -3 in the context of Trichomonas infectio

36 Inhibitors for galectin-1 and -3 were synthesized from thiodigalactosid

37 The homodimeric adhesion/growth-regulatory galectin-1 and a set of covalently linked homo-oligomers

38 there was a significant correlation between galectin-1 and CA IX staining (P = .01) and a strong inv

39 01) and a strong inverse correlation between galectin-1 and CD3 staining (P = .01).

40 s and revealed concomitant overexpression of galectin-1 and CXCR4 associated adversely with overall a

41 ignificance and positive correlation between galectin-1 and CXCR4 expression levels and revealed conc

42 The coordinated upregulation of galectin-1 and CXCR4 may be a novel prognostic factor fo

43 We have shown that galectin-1 and galectin-3 are functionally redundant spl

44 Previously, we showed that galectin-1 and galectin-3 are redundant pre-mRNA splicin

45 Using the example of homodimeric galectin-1 and monomeric galectin-3, the mutual design c

46 Concomitant incubation with exogenous galectin-1 and morphine potentiated HIV-1 infection of M

47 f 3.10(-7) M, and specific as CD146 binds to Galectin-1 and not to Galectin-2.

48 mmunosuppressive microenvironment, including galectin-1 and PD-L1/2.

49 the specificity of Gal-3BP interacting with galectin-1 and the role of Gal-3BP in cancer cell aggreg

50 ghly up-regulated genes include SOX5, CD11C, galectin-1, and FGR, similar to a previously described F

51 Here, we report the identification of galectin-1, and related galectins, as a novel OCA-B-inte

52 that nanoplexes silenced gene expression for galectin-1, and they reversed the effects of morphine on

53 polypeptide, apolipoproteins A-Ib and A-II, galectin-1, and vitellogenin-6 during degeneration when

54 In a murine lymphedema model, galectin-1(-/-) animals had increased numbers of migrato

55 Furthermore, recombinant galectin-1 antagonized binding of agonist tetramers to t

56 Preincubation of exosomes with anti-galectin 1 antibody decreased their neuroprotective effe

57 Because both CD146 and Galectin-1 are involved in modulation of cell apoptosis,

58 Our results also support a critical role for galectin-1 as a GM1 cross-linking counter-receptor that

59 This study thus identifies Galectin-1 as a master regulator of clinically relevant

60 Altogether, our results identify Galectin-1 as a novel ligand for CD146 and this interact

61 R of OT-1 thymocytes, these studies identify galectin-1 as a tuner of TCR binding, signaling, and fun

62 general, our data indicate that 0118 targets galectin-1 as an allosteric inhibitor of glycan/carbohyd

63 oscopy demonstrates that 0118 indeed targets galectin-1 at a site away from the lectin's carbohydrate

64 Binding to galectin-1 at the extracellular surface prevents clathri

65 -mediated glycosylation of RPTPbeta promotes galectin-1 binding and RPTPbeta levels of retention on t

66 Moreover, galectin-1 binding clustered CD43 modified with either c

67 ts in decreased RPTP retention, showing that galectin-1 binding contributes to the increased retentio

68 The galectin-1 binding domain in OCA-B has been localized to

69 Glycan-dependent Galectin-1 binding induced a set of disease markers, inc

70 lated, contributes a significant fraction of galectin-1 binding sites on T cells, as T cells lacking

71 pression of core 2 O-glycans did not enhance galectin-1 binding to CD43 on T cells.

72 and the effects of O-glycan modification on galectin-1 binding to CD43.

73 Galectin-1 binding to surface CD43 and CD45 on MDDCs ind

74 The sugar-galectin-1 binding was also examined.

75 Galectin-3 and galectin-1, binding partners of LGALS3BP, potentiate mon

76 studies showed that after klotho treatment, galectin-1 binds the TRPV5 N-glycan and thereby increase

77 Galectin-1 binds to N- and O-glycans on several glycopro

78 Specifically, galectin-9 and galectin-1 both kill thymocytes, peripheral T cells, and

79 in-1-induced cross-linking and T cell death, galectin-1 bound to CD43 fusion proteins modified with e

80 was blocked by intracellular Bcl-2, whereas galectin-1, but not galectin-9, T cell death was blocked

81 Galectin-1, but not lipopolysaccharide, stimulated Syk p

82 The interaction of OCA-B and galectin-1 can be detected both in vivo and in vitro.

83 , providing an additional mechanism by which galectin-1 can dampen immune responses.

84 s, in the present study, we demonstrate that galectin-1 can enhance NiV attachment to and infection o

85 Thus, galectin-1 can have dual and opposing effects on NiV inf

86 Interestingly, we also found that galectin-1 can prime DCs to respond more quickly to low

87 Endogenous human lectins, such as galectin-1, can function as pattern recognition receptor

88 s of bivalent constructs with galectin-9 and galectin-1 carbohydrate recognition domains connected by

89 However, as galectin-3 and galectin-1 cell death are neither additive nor synergist

90 itated with galectin antisera, we found that galectin-1 containing spliceosomes did not contain galec

91 sensitivity of GluA4 AMPA receptors to human galectin-1 could be enhanced by supplementation of cultu

92 tion of cell apoptosis, we hypothesized that Galectin-1 could interact with CD146, leading to functio

93 The major galectin-1 counter-receptor on both dendritic cell popul

94 on, with loss of core 2 O-glycan ligands for galectin-1 created by core 2 beta1,6-N-acetylglucosaminy

95 n patients with renal cell carcinoma and the galectin-1-CXCR4 axis may serve as a therapeutic target

96 hocytes in TLR5-responsive tumors to secrete galectin-1, dampening antitumor immunity and acceleratin

97 Loss of CD43 expression reduced galectin-1 death of murine thymocytes and human T lympho

98 ne externalization or DNA degradation during galectin-1 death.

99 ced ERK signaling was sustained in activated galectin-1-deficient CD8 T cells and antagonized by reco

100 We found that galectin-1-deficient CD8 T cells undergo greater cell di

101 In vitro experiments demonstrated that galectin-1-deficient GL26-Cit glioma cells are approxima

102 Conversely, galectin-1-deficient glioma cells could be eradicated by

103 Binding of dimeric galectin-1 (dGal-1) to glycoconjugates on N-formyl-Met-L

104 lls, whereas LNCaP cells that do not express galectin-1 did not kill T cells.

105 Extracellular galectin-1 directly induces death of T cells and thymocy

106 Recombinant galectin-1 enhanced TCR binding to agonist/MHC complexes

107 y, we underscore the biological relevance of galectin-1-enhanced DC migration by showing that intrade

108 ssue of Immunity, Starossom et al. show that Galectin-1 exerts a neuroprotective function through gly

109 ll fusion and damage, depending on timing of galectin-1 exposure.

110 re sensitive to NK-mediated tumor lysis than galectin-1-expressing cells.

111 umor evasion of immune attack; we found that galectin-1-expressing prostate cancer cells killed bound

112 Galectin-1 expression also promoted TCR agonist-driven C

113 increased cathepsin-V (CTSV) expression and galectin-1 expression and secretion in human glomerular

114 In contrast, galectin-1 expression antagonized ERK activity in thymoc

115 unoblots and PCR studies confirmed increased galectin-1 expression by hypoxia in several cancer cell

116 Galectin-1 expression opposed TCR partial agonist-driven

117 B cells lacking OCA-B expression, increased galectin-1 expression, secretion, and cell surface assoc

118 and they reversed the effects of morphine on galectin-1 expression.

119 es (actin and myosin), ECM genes (Collagens, Galectin-1, Fibronectin, Heparan Sulfate, LOX, FAK1), ce

120 The binding affinity and specificity of galectin-1 for eight different beta-galactosyl terminal

121 s had no surface galectin-3 but used surface galectin-1 for interaction with Gal-3BP to form large ol

122 Galectin-1 (Gal-1) and galectin-3 (Gal-3) exhibit profou

123 t interactions between the regulatory lectin galectin-1 (Gal-1) and specific target N-glycans link tu

124 Following the identification of Galectin-1 (Gal-1) as a downstream effector of p75(NTR),

125 hort, which revealed that increased lymphoma galectin-1 (Gal-1) expression strongly correlated with r

126 Galectin-1 (Gal-1) has been shown to play a major role i

127 tle is known about the role(s) of endogenous galectin-1 (Gal-1) in arthritis.

128 Here we show that Galectin-1 (Gal-1) induces PS exposure independent of al

129 Galectin-1 (Gal-1) is a beta-galactoside-binding protein

130 Galectin-1 (gal-1) is an endogenous lectin with regulato

131 By binding cell surface glycoconjugates, galectin-1 (gal-1) is involved in cell adhesion and migr

132 At concentrations that abrogated galectin-1 (Gal-1) ligand and E-selectin ligand expressi

133 It was recently described that Galectin-1 (Gal-1) promotes axonal growth after spinal c

134 fabricated for the quantitative detection of Galectin-1 (Gal-1) protein, a biomarker for the onset of

135 Galectin-1 (Gal-1) regulates leukocyte turnover by induc

136 fferent stages of the disease, we found that galectin-1 (Gal-1) was the most abundantly expressed gal

137 Galectin-1 (Gal-1), a beta-galactoside-binding lectin, p

138 Galectin-1 (Gal-1), a beta-galactoside-binding protein,

139 Tumor-derived galectin-1 (Gal-1), a beta-galactoside-binding S-type le

140 Galectin-1 (Gal-1), a carbohydrate-binding protein whose

141 Galectin-1 (Gal-1), a glycan-binding protein with broad

142 Galectin-1 (Gal-1), a member of a family of carbohydrate

143 Galectin-1 (Gal-1), a member of a family of evolutionari

144 Galectin-1 (gal-1), a special lectin with high affinity

145 Galectin-1 (Gal-1), an endogenous glycan-binding protein

146 dy we evaluated the therapeutic potential of galectin-1 (gal-1), an endogenous lectin that in some au

147 We investigated the ability of soluble galectin-1 (gal-1), an endogenous lectin that promotes T

148 Here we show that galectin-1 (Gal-1), an endogenous lectin that recognizes

149 Galectin-1 (Gal-1), an evolutionarily conserved beta-gal

150 Moreover, using galectin-1 (Gal-1), an immunomodulatory carbohydrate-bin

151 In this article, we show that galectin-1 (Gal-1), an immunoregulatory lectin widely ex

152 One of these regulators, galectin-1 (Gal-1), possesses both anti-inflammatory and

153 dy, we identified a new fibrosis gene called galectin-1 (Gal-1), which is highly expressed in tubular

154 a binding partner for the endogenous lectin galectin-1 (Gal-1), which is known to ameliorate symptom

155 Galectin-1 (Gal-1)-binding to Gal-1 ligands on immune an

156 lopment, bone marrow stromal cells secreting galectin-1 (GAL1) constitute a specific niche for pre-BI

157 Galectin-1 (Gal1) is a member of a highly conserved fami

158 Galectin-1 (GAL1) is an S-type lectin with multiple func

159 The glycan-binding protein galectin-1 (Gal1) is highly expressed in PDAC stroma, bu

160 We noted that tumor galectin-1 (Gal1) levels were inversely correlated with

161 l lines (LCLs) and primary PTLDs overexpress galectin-1 (Gal1), a carbohydrate-binding lectin that in

162 These include galectin-1 (gal1), a lectin with apoptotic activity on a

163 Galectin-1 (Gal1), an endogenous glycan-binding protein,

164 Here, we identified Galectin-1 (Gal1), an endogenous glycan-binding protein,

165 Galectin-1 (Gal1), an evolutionarily conserved glycan-bi

166 We previously showed that galectin-1 (GAL1), produced by bone marrow stromal cells

167 the immunoregulatory glycan-binding protein, galectin-1 (Gal1), through an AP1-dependent enhancer.

168 ace glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-g

169 core 2 O-glycans (high affinity ligands for galectin-1), galectin-1 signaling in cells expressing a

170 osis similar to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests

171 In this article, we show that galectin-1 gene and protein expression are potentiated b

172 Knockdown of galectin-1 gene expression in renal cancer cell lines re

173 tor, TGF-beta, hepatocyte growth factor, and galectin-1 gene expression levels varied among donors.

174 1 susceptibility and synthesis of endogenous galectin-1 has been proposed to promote tumor evasion of

175 positively regulate T cell susceptibility to galectin-1, identifying a novel function for CD43 in con

176 Vimentin, cystatin C, galectin-1, IGFBP-7, and secreted protein, acidic and ri

177 We found significant overexpression of galectin-1 in both kidney cancer cell lines and metastat

178 mphatic endothelial cells, and deposition of galectin-1 in extracellular matrix selectively regulates

179 roviding additional evidence for the role of galectin-1 in immune-endocrine cross-talk.

180 These findings define a novel role for galectin-1 in inhibiting tissue emigration of immunogeni

181 However, the role of galectin-1 in kidney cancer remains elusive.

182 ion by showing that intradermal injection of galectin-1 in MRL-fas mice, which have a defect in skin

183 mergence of hormonal and redox regulation of galectin-1 in placental mammals may be implicated in mat

184 we show conserved placental localization of galectin-1 in primates and its predominant expression in

185 This study evaluated the role of galectin-1 in the progression and clinical prognosis of

186 Silencing galectin-1 increased and adding exogenous galectin-1 sup

187 t CD8 T cells and antagonized by recombinant galectin-1, indicating galectin-1 modulates TCR feed-for

188 eficient cells displayed enhanced binding to galectin-1, indicating that changes in GNE activity can

189 Thus, extracellular galectin-3 and galectin-1 induce death of T cells through distinct cell

190 ted, we propose that increased expression of galectin-1 induced by morphine may modulate HIV-1 infect

191 Additional studies suggested that galectin-1 induced CXCR4 expression through activation o

192 Resistance to galectin-1-induced apoptosis may directly contribute to

193 However, events in galectin-3- and galectin-1-induced cell death differ in a number of ways

194 CD45, or if fodrin degradation is prevented, galectin-1-induced cell death is not accompanied by memb

195 other glycoprotein receptors is critical for galectin-1-induced cross-linking and T cell death, galec

196 Syk and protein kinase C signaling abrogated galectin-1-induced DC activation as monitored by interle

197 lthough roles for CD7 and CD45 in regulating galectin-1-induced death have been described, the requir

198 In addition, CD7 that is required for galectin-1-induced death is not required for death trigg

199 We describe a novel role for CD43 in galectin-1-induced death, and the effects of O-glycan mo

200 We observed a Galectin-1-induced HUVEC apoptosis in a dose-dependent m

201 MDDCs and immediate downstream effectors of galectin-1-induced MDDC activation and migration.

202 ly and promoting phagocytic clearance during galectin-1-induced T cell death.

203 In this study, we show that galectin-1 induces a phenotypic and functional maturatio

204 Therefore, galectin-1, inducibly expressed by activated CD8 T cells

205 The presence of galectin-1 inhibits migration of immunogenic dendritic c

206 -immunoprecipitation experiments showed that Galectin-1 interacts with endogenous CD146 that is highl

207 ain of galectin-3 inhibited incorporation of galectin-1 into splicing complexes, explaining the domin

208 Galectin-1 is a galactoside-binding lectin expressed in

209 Galectin-1 is a lectin produced by vascular cells that c

210 Galectin-1 is a member of a family of beta-galactoside-b

211 Galectin-1 is a member of the conserved beta-galactoside

212 Galectin-1 is a new fibrosis protein in type 1 and type

213 Our findings show that galectin-1 is a novel endogenous activator of human MDDC

214 Here, we show that galectin-1 is also highly expressed by human lymphatic e

215 Galectin-1 is an anti-inflammatory lectin with pleiotrop

216 Galectin-1 is an endogenous carbohydrate-binding protein

217 Galectin-1 is an endogenous carbohydrate-binding protein

218 The mammalian lectin galectin-1 is highly expressed by vascular endothelial c

219 Galectin-1 is involved in pathological disorders like tu

220 Galectin-1 is known to play a role in immune regulation

221 is, galectins, we tested the hypothesis that Galectin-1 is relevant for causing degeneration.

222 Finally, galectin-1 is shown to negatively regulate B cell prolif

223 One unique effect of galectin-1 is to increase DC migration through the ECM,

224 f core 1 O-glycans (low affinity ligands for galectin-1) is sufficient to overcome lack of core 2 O-g

225 between the two galectins, as galectin-9 and galectin-1 killed different subsets of murine thymocytes

226 susceptibility to the two galectins: whereas galectin-1 kills double-negative and double-positive hum

227 Galectin-1 kills immature thymocytes and activated perip

228 Galectin-1 knockdown decreased CXCR4 expression levels i

229 Moreover, mice injected with galectin-1 knockdown Lewis lung carcinoma showed decreas

230 Binding to galectin-1 lattice at the extracellular surface leads to

231 Importantly, at the genes encoding galectin-1 (Lgals1), and mothers against decapentaplegic

232 he secreted beta-galactoside binding protein Galectin 1-like 2 (Drgal1-L2).

233 C migration through the ECM, suggesting that galectin-1 may be an important component in initiating a

234 We observed direct evidence for galectin-1-mediated extended cross-linking on the engine

235 hibitors led to dose-dependent impairment of Galectin-1-mediated transcriptional activation.

236 onized by recombinant galectin-1, indicating galectin-1 modulates TCR feed-forward/feedback loops inv

237 In order to exhibit an enhancing effect, galectin-1 must be present during the initial phase of v

238 gonists of the effect of lung cancer-derived galectin-1 on DCs and anti-HB-EGF blocking antibodies co

239 common death trigger receptors recognized by galectin-1 on different types of cancer cells.

240 to contribute to the differential effect of galectin-1 on migration.

241 relevant and exploitable for PET imaging of galectin-1-overexpressing bladder tumors.

242 umulation of the carbohydrate radiotracer in galectin-1-overexpressing UMUC3 orthotopic tumors when i

243 f virus attachment; in contrast, addition of galectin-1 postinfection results in reduced production o

244 Treatment of galectin-1, present in large amounts in lung cancer cond

245 Finally, galectin-1 produced by activated Ag-specific CD8 T cells

246 dentify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF recep

247 Our findings suggest that galectin-1 promotes tumor progression through upregulati

248 Here, we identify the galectin-1 receptors on MDDCs and immediate downstream e

249 ; however, we have found that galectin-9 and galectin-1 require different glycan ligands and glycopro

250 t for loss of core 2 O-glycan expression and galectin-1 resistance.

251 though MF cells are typically CD7-, and thus galectin-1 resistant, CD7+ HH cells, derived from a pati

252 minyltransferase, which is down-regulated in galectin-1-resistant PSA(-) LNCaP cells compared with ga

253 ositive (PSA(+)) LNCaP cells compared with a galectin-1-resistant PSA(-) LNCaP subclone.

254 e first to indicate that lung cancer-derived galectin-1 secretion is responsible for stimulating tumo

255 1-resistant PSA(-) LNCaP cells compared with galectin-1-sensitive PSA(+) LNCaP cells.

256 d expression of glycosyltransferase genes in galectin-1-sensitive, prostate-specific antigen-positive

257 an ligands that are important for conferring galectin-1 sensitivity in these cells, and analyzed expr

258 To understand the mechanism of galectin-1 sensitivity of LNCaP cells compared with othe

259 nsferase 1 rendered LNCaP cells resistant to galectin-1, showing that specific O-glycans are critical

260 Furthermore, regulation of galectin-1 signaling by alpha2,6-sialylation of N-glycan

261 cans (high affinity ligands for galectin-1), galectin-1 signaling in cells expressing a high molecula

262 While galectin-1 signaling in cells expressing low molecular w

263 Here we show that galectin-1 signaling through CD45, which carries both N-

264 ells, and restoration of CXCR4 expression in galectin-1-silenced cells rescued cell motility and clon

265 lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1-induced upregulation of

266 notechnology approach that uses gold nanorod-galectin-1 small interfering RNA complexes (nanoplexes)

267 ity to galectin-3 but maintained affinity to galectin-1 suppressed chemokine expression.

268 ng galectin-1 increased and adding exogenous galectin-1 suppressed chemokine responses to Trichomonas

269 Galectin-1 suppressed chemokines that facilitate recruit

270 Our findings suggest that galectin-1 suppression in human glioma could improve pat

271 Loss of galectin-1 susceptibility and synthesis of endogenous ga

272 is the same glycosyltransferase required for galectin-1 susceptibility of T lymphoma cells, indicatin

273 ing that specific O-glycans are critical for galectin-1 susceptibility.

274 e show that fodrin degradation occurs during galectin-1 T cell death and that CD45 is essential for f

275 Thus, N- and O-glycans modulate galectin-1 T cell death by distinct mechanisms, and diff

276 Regulation of galectin-1 T cell death by O-glycans is mediated through

277 lular death pathways, as galectin-9, but not galectin-1, T cell death was blocked by intracellular Bc

278 Although 0118 is a topomimetic of galectin-1-targeting angiostatic amphipathic peptide Ang

279 ls lacking CD43 bound approximately 50% less galectin-1 than T cells expressing CD43.

280 are resistant to apoptotic agents, including galectin-1 that is abundant in skin.

281 ial cells express the innate immune effector galectin-1 that we have previously shown can bind to spe

282 t the acquired immunoregulatory functions of galectin-1 then became highly conserved in eutherian lin

283 es likely impart their effect via binding of galectin 1 to cells.

284 assays show that 0118 attenuates binding of galectin-1 to cell surface glycans, and the inhibition o

285 Binding of galectin-1 to immunogenic dendritic cells reduces phosph

286 increased the preference for galectin-3 over galectin-1 to more than 200-fold.

287 Indeed, compared with LPS, galectin-1-treated human MDDCs exhibited significantly b

288 However, unlike LPS-matured DCs, galectin-1-treated MDDCs did not produce the Th1-polariz

289 Immature human MDDCs exposed to galectin-1 up-regulated cell surface markers characteris

290 unohistochemical analysis substantiated that Galectin-1 upregulation is associated with osteoarthriti

291 ar-dependent binding of recombinant CD146 to Galectin-1 using both ELISA and Biacore assays.

292 Galectin 1 was highly expressed on the surface of PMSCs

293 A growth inhibitor, galectin-1, was downregulated in the high producer, whic

294 However, galectin-3, but not galectin-1, was expressed in the DCT.

295 of the tandem repeat galectin-9 and dimeric galectin-1, we created a series of bivalent constructs w

296 Plasma levels of galectin-1 were higher in tumor-bearing severe combined

297 2 O-glycan expression and susceptibility to galectin-1, whereas mutant enzyme lacked activity and di

298 The proteomic analysis revealed upregulated galectin-1, which is an immunomodulatory protein linked

299 We found that galectin-1, which is made by inflamed endothelial cells,

300 In this way, galectin-1 widens the distinction between TCR-directed f

301 ns, and a reported inhibitory interaction of galectin-1 with CD45, the phosphatase activity of CD45 i